MedTrace Logo

Hypothermic Machine Perfusion With Omnisol of Deceased Donor Kidneys Prior to Transplantation

NCT07792317 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-08-28

No results posted yet for this study

Summary

Insufficient availability of organs from brain dead (DBD) and living donors has necessitated increased use of less than optimal organs from donation after cardiac death (DCD) or from extended criteria donors. Preservation of DCD organs using the current clinically applied preservation solutions is associated with up to 73% incidence of delayed graft function, highlighting the need for new preservation solutions designed to improve early graft function.

Omnisol is expected to result in equivalent or improved kidney preservation as compared to currently marketed organ preservation solutions used for HMP.

Conditions

  • Kidney Transplant
  • Kidney Failure
  • Renal and Urinary Tract Therapeutic Procedures
  • End Stage Renal Disease (ESRD)

Interventions

DEVICE

Omnisol organ preservation solution

Omnisol for HMP of deceased donor kidneys

Sponsors & Collaborators

  • Vivalyx GmbH

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-17
Primary Completion
2026-11-30
Completion
2026-11-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07792317 on ClinicalTrials.gov